The path to breakthroughs in anti-hepatitis B virus treatment
10.3760/cma.j.cn112866-20250705-00139
- VernacularTitle:抗乙型肝炎病毒治疗破局之路
- Author:
Huimin LIU
1
;
Qing MAO
1
Author Information
1. 陆军军医大学（第三军医大学）西南医院感染病科 病毒传染病精准防治重庆市重点实验室，重庆 400038
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Chronic infection;
Antiviral therapy;
New drug development
- From:
Chinese Journal of Experimental and Clinical Virology
2025;39(4):393-396
- CountryChina
- Language:Chinese
-
Abstract:
Over the past three decades，despite advancements in immunization and antiviral therapies，chronic hepatitis B（CHB）has remained a major global public health challenge. The urgent priority now lies in preventing and reducing the progression of CHB to end-stage liver disease. At present，the most effective approach is the early initiation of anti-hepatitis B virus（HBV）therapy，which has also become a critical objective in recent guidelines issued by major authoritative bodies to expand the indications for anti-HBV treatment. This article provides a comprehensive review of several key aspects，including the efficacy and limitations of nucleos（t）ide analogs（NAs），the role and challenges of interferon（IFN）in achieving clinical cure，the current status and future prospects of novel anti-HBV drugs，and the outlook for emerging anti-HBV strategies.
